"Note 20 ...... Nucleus Therapeutics – Yale University –...

"Note 20
......

Nucleus Therapeutics – Yale University – License, Commercialization and Development Agreement
In March of 2016, Patrys acquired the private Company Nucleus Therapeutics Pty Ltd, in order to obtain the global license for the development as anti-cancer agents the antibodies 3E10 and 5C6 from Yale University. Once developed, certain milestone payments and royalties will be payable to Yale University regarding products that derive from 3E10 and/or 5C6. These milestones and royalties are typical in the industry for transactions of this nature.

Payload Therapeutics – Yale University – License, Commercialization and Development Agreement
In June of 2017, Payload Therapeutics (a wholly-owned subsidiary of Patrys) obtained the global license for the development as anti-cancer agents the antibodies 3E10 nanoparticles from Yale University. Once developed, certain milestone payments and royalties will be payable to Yale University regarding products that derive from 3E10 nanoparticles. These milestones and royalties are typical in the industry for transactions of this nature."

According to ASIC register, Nucleus Therapeutics was registered on 28 Mar 2015 and Payload Therapeutics on 23 May 2017.

In the Announcement dated 29 Mar 2016, it says "Patrys has acquired the license for the novel anti-DNA antibody platform through a scrip acquisition, of Nucleus Therapeutics Pty Ltd (Nucleus) in a tranched transaction with a value of up to A$720,000". So far Nucleus Therapeutics has been paid around 85 mil shares by Patrys who claimed in the Annual Report 2017 that it had acquired Nucleus Therapeutics in Mar 2016. As such, Patrys must be the largest shareholder who owns the majority of Nucleus shares.

In the Announcement dated 13 Jun 2017, no information about Payload Therapeutics Pty Ltd can be found. The reason could be Payload Therapeutics is wholly owned subsidiary of Patrys and can be legally represented by its parent company in the ann even if it's a signatory party in the licensing agreement with Yale.

It seems the company respectively use two slightly different deal structures for the two licences from Yale.